Fibrous dysplasia (monostotic), other site
Methodology & AI Transparency ⓘ
Fibrous dysplasia (monostotic), other site Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Fibrous dysplasia (monostotic), other site (M85.08) in Bone Density relies on dual-energy X-ray absorptiometry in Fibrous dysplasia (monostotic), other site (M85.08: (DEXA) with FRAX), guiding step-wise therapeutic adjustments toward Serum Calcium, Phosphorus in Fibrous dysplasia (monostotic), other site (M85.08: & PTH) (Ca 8.9–10.1 mg/dL; PTH 15–65 pg/mL (M85.08)).
- 2 Real-world patient consensus: Diagnostic registry M85.08: Fibrous dysplasia (monostotic), other site is managed within Bone Density.
- 3 Typical cash cost range: Clinicians assessing Fibrous dysplasia (monostotic), other site focus on cortical porosity [Fibrous dysplasia (monostotic), other site M85.08] and targeted history.
- 4 Top reported side effects / signs: Longitudinal Fibrous dysplasia (monostotic), other site monitoring tracks 25-Hydroxy Vitamin D [Fibrous dysplasia (monostotic), other site M85.08] toward 40 – 65 ng/mL (M85.08).
Ask our AI Specialists anything about Fibrous dysplasia (monostotic), other site
What Is Fibrous dysplasia (monostotic), other site?
Clinical triage of Fibrous dysplasia (monostotic), other site (M85.08) in Bone Density relies on dual-energy X-ray absorptiometry in Fibrous dysplasia (monostotic), other site (M85.08: (DEXA) with FRAX), guiding step-wise therapeutic adjustments toward Serum Calcium, Phosphorus in Fibrous dysplasia (monostotic), other site (M85.08: & PTH) (Ca 8.9–10.1 mg/dL; PTH 15–65 pg/mL (M85.08)).
Pathophysiology, Underlying Causes & Clinical Presentation
In Fibrous dysplasia (monostotic), other site (M85.08), physiological disruption stems from cortical porosity [Fibrous dysplasia (monostotic), other site M85.08], informing Osteoporosis, Vitamin D & Bone Density protocols that track Serum Calcium, Phosphorus in Fibrous dysplasia (monostotic), other site (M85.08: & PTH) (Ca 8.9–10.1 mg/dL; PTH 15–65 pg/mL (M85.08)).
Common Symptoms & Clinical Signs
- • Presentation of Fibrous dysplasia (monostotic), other site (M85.08): fragility fracture of in Fibrous dysplasia (monostotic), other site (M85.08: wrist, hip, or)
- • Secondary Fibrous dysplasia (monostotic), other site clinical sign: gradual loss of in Fibrous dysplasia (monostotic), other site (M85.08: standing height)
- • Symptom flares in Fibrous dysplasia (monostotic), other site correlating with 25-Hydroxy Vitamin D [Fibrous dysplasia (monostotic), other site M85.08] deviation outside 40 – 65 ng/mL (M85.08)
- • Functional bone density impact requiring dual-energy X-ray absorptiometry in Fibrous dysplasia (monostotic), other site (M85.08: (DEXA) with FRAX) evaluation (M85.08)
Fibrous dysplasia (monostotic), other site Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M85.08 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoporosis, Vitamin D & Bone Density | NLM Clinical Tables |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D [Fibrous dysplasia (monostotic), other site M85.08] | 40 – 65 ng/mL (M85.08) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Calcium, Phosphorus in Fibrous dysplasia (monostotic), other site (M85.08: & PTH) | Ca 8.9–10.1 mg/dL; PTH 15–65 pg/mL (M85.08) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CTX / P1NP in Fibrous dysplasia (monostotic), other site (M85.08: Bone Turnover Markers) | Balanced remodeling on therapy (M85.08) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Fibrous dysplasia (monostotic), other site
Treatment selection for Fibrous dysplasia (monostotic), other site depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Fibrous dysplasia (monostotic), other site)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Complications of orthopedic treatment in patients diagnosed with X-linked In average, one complication occurred per surgery and the severity of complications were substantial. Journal of pediatric endocrinology & metabolism : JPEM • 2022-08-26 • Phase III Randomized Trial | N = 79 | 82/100 | PMID 35700440 ↗ |
| Can This Approach Help? Inside the Latest Research on How the body absorbs the medicine and bioequivalence of a rosuvastatin/ezetimibe The rosuvastatin/ezetimibe (10/10 mg) FDC was bioequivalent to single agents concomitantly administered. International journal of clinical pharmacology and therapeutics • 2018-01-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 29162214 ↗ |
| Can This Approach Help? Inside the Latest Research on How the body absorbs the medicine and Safety of a Fixed-dose Combination of Sixty-four healthy Korean subjects were enrolled, and 57 subjects completed the study. Clinical therapeutics • 2017-09-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 28803122 ↗ |
| Can This Approach Help? Inside the Latest Research on Relative bioavailability of 2 prototype fixed-dose combination formulations for The FDC formulations demonstrated similar bioavailability to coadministered commercially available amlodipine and rosuvastatin. Clinical pharmacology in drug development • 2016-03-15 • Randomized Controlled Trial | N = 12 | 82/100 | PMID 27138026 ↗ |
Fibrous dysplasia (monostotic), other site Patient Community & “People Like Me” Threads
Filter Fibrous dysplasia (monostotic), other site community threads and patient logs by age, biological sex, dosage, and treatment duration.